NCT05488392

Brief Summary

Hypothermia with intrajugular cooling is a neuroprotective strategy that has been proven to minimize brain damage and maximize functional preservation in animal models of stroke. The purpose of this proof-of-concept study is to determine the safety and tolerability of intrajugular cooling in patients with acute ischemic stroke who are treated with mechanical thrombectomy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 3, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 4, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

November 1, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2024

Completed
Last Updated

August 4, 2022

Status Verified

August 1, 2022

Enrollment Period

1 year

First QC Date

August 3, 2022

Last Update Submit

August 3, 2022

Conditions

Keywords

acute ischemic strokehypothermiathrombectomyintrajugular cooling

Outcome Measures

Primary Outcomes (1)

  • Number of participants with major response

    Major response is any of the following: 1. Cerebral venous system damage; 2. Cerebral venous thrombosis; 3. Huge hematoma at the puncture site requiring surgical intervention; 4. Malignant arrhythmia within 24 hours; 5. Cardiac arrest within 24 hours; 6. Myocardial infarction within 24 hours; 7. Congestive heart failure within 24 hours. In the 3 + 3 design, 3 subjects are recruited for a given intrajugular cooling dose level. The trial is stopped if ≥ 2 of 3 subjects at a given dose level show major response. If only 1 of 3 subjects shows major response, 3 more subjects are recruited at a given dose level and a major response in any of them will stop the trial. Otherwise, same procedure is followed for the next dose level. Maximum tolerable dose will be the dose at the level before stopping of the trial. The schedule of advancing duration is 10 min, 15 min, 20 min, 25 min, and 30 min.

    Within 24 hours after hypothermia with intrajugular cooling

Study Arms (1)

Intrajugular cooling group

EXPERIMENTAL

The safety and tolerability of hypothermia with intrajugular cooling will be investigated using 3+3 dose-escalation trial design.

Procedure: Hypothermia with intrajugular cooling

Interventions

Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.

Intrajugular cooling group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-80 years;
  • Acute ischemic stroke caused by unilateral internal carotid artery terminal segment/middle cerebral artery M1 segment occlusion;
  • In line with the indications for mechanical thrombectomy without contraindications;
  • Successful recanalization (mTICI 2b/3) after mechanical thrombectomy that confirmed by digital subtraction angiography;
  • Written informed consent provided by the patients or their legal relatives.

You may not qualify if:

  • Suffering from cerebral venous system diseases such as cerebral venous thrombosis/stenosis/dysplasia;
  • Suffering from heart diseases such as ventricular arrhythmia/myocardial infarction/congestive heart failure;
  • Imaging examination after mechanical thrombectomy shows intracranial hemorrhage/contrast extravasation;
  • Difficulty in reaching the designated position of the device used for intrajugular cooling;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ischemic StrokeHypothermia

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Xunming Ji, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 3, 2022

First Posted

August 4, 2022

Study Start

November 1, 2022

Primary Completion

November 1, 2023

Study Completion

February 1, 2024

Last Updated

August 4, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will share

Related data will be shared if full study protocol and statistical analysis plan are provided with reasonable design.